Brookstone Pharmaceuticals, LLC today announced the introduction of Ranitidine Syrup, a generic equivalent to Zantac® Syrup (ranitidine hydrochloride). Ranitidine, part of the Histamine-2 blockers, is used to treat and prevent ulcers in the stomach and intestines. It can also be used to treat gastro... - July 21, 2008 - Brookstone Pharmaceuticals, LLC

The formulation development company’s services are led by an industry pioneer. - June 22, 2008 - Xcelience, LLC

The Tampa-based CRO and its chief executive are voted as best company and CEO of the year. - May 26, 2008 - Xcelience, LLC

With the launch of Hovid’s new online store, hovid.sg, the premium products Hovid was recognized for will be made even more popular. The Singaporean market is seen as having big potential in terms of online users purchasing through the web, especially those engaged in the pharmaceutical industry. - May 08, 2008 - Hovid

The Tampa-based CRO continues its perpetual growth with new XRD support. - May 08, 2008 - Xcelience, LLC

CEAT Ltd, the flagship company of the 13,500 crore RPG Group and one of India’s leading tyre manufacturers has today signed an agreement with M/s. Ashford InfoTech Limited for development of a vacant portion of about 7 acres of land located at Village Road in Bhandup, Mumbai. The proceeds of the... - March 12, 2008 - RPG

The FDA has approved PRISTIQ (desvenlafaxine), an SNRI, to treat adult patients with major depressive disorder (MDD). Wyeth expects to begin shipping PRISTIQ to wholesalers beginning in the second quarter of 2008. - March 01, 2008 - Wyeth Pharmaceuticals

The Tampa-based CRO is first to acquire next generation Xcelodose. - January 26, 2008 - Xcelience, LLC

Samaritan has appointed two new independent members, Jack L. Ayala and Robert W. Crane, to its Board of Directors. Mr. Ayala and Mr. Crane bring valuable experience and their appointment strengthens Samaritan's commitment to maintain a majority of independent members that reflects today's best practices on its Board. Samaritan's board is now comprised of eight independent directors and two internal directors. - January 09, 2008 - Samaritan Pharmaceuticals

Samaritan has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 09, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals has received a notice that a European Patent has been granted to Samaritan's SP-1000 (Cholesterol Recognition Sequence) drug for the treatment of cardiovascular disease. - January 09, 2008 - Samaritan Pharmaceuticals

Enters Service Agreement with Advinus Therapeutics, India to Validate Potential Memory Restoring Benefits of Alzheimer's Drug Caprospinol. Strategy is to Bolster Caprospinol Alzheimer's Data Package to Out-License to Big Pharma and Expand IND Application to Enter Human Trials. Samaritan Pharmaceuticals... - January 09, 2008 - Samaritan Pharmaceuticals

The U.S. Food and Drug Administration (FDA) has completed its regulatory review of Samaritan's IND (Investigational New Drug) application for Cushing's syndrome SP-6300 and declared it has not identified any deficiencies in its IND filing. Accordingly, Samaritan can proceed with its proposed Phase II clinical study of Cushing's syndrome SP-6300's efficacy in patients experiencing Hypercortisolism. - January 04, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals, Inc. is pleased to announce that its subsidiary Samaritan Pharmaceuticals Europe, S.A. has received notification, from the Cyprus Ministry of Health, that its marketing authorization for HIV fungus drug Amphocil has been approved in Cyprus. The Cyprus Ministry of Health is... - January 03, 2008 - Samaritan Pharmaceuticals

Ms. Anna Strasberg has joined Samaritan's Advisory Board. Anna Strasberg is best known for continuing the Actors Studio, where the work of her husband Lee Strasberg nurtured the talents of celebrities like Marlon Brando, Robert De Niro, Harvey Keitel, Paul Newman and Al Pacino. - January 03, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 03, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals, Inc. has signed an exclusive distribution agreement with EUSA Pharma to launch, promote, sell and support pain patch Rapydan in Greece and Cyprus. - January 03, 2008 - Samaritan Pharmaceuticals

The annual art camp by the RPG Academy of Art concluded with a warm brunch at the Marve beach house today. Pristine white was the theme of the locale and the breezy touch of sea winds along with the live band playing some groovy numbers got the enchantment heightened. After the week-long camp, the participating... - December 30, 2007 - RPG

•Rs. 391 Crores win in Abu Dhabi; Largest single win ever, in dollar value terms, for KEC •Rs. 246 crores turnkey contract in Algeria - December 01, 2007 - RPG

•Rs. 260 Crores Turnkey contract in Saudi Arabia •Rs. 140 Crores Turnkey contract in Namibia - December 01, 2007 - RPG

In an in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals, Inc. has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in vitro data and suggests Caprospinol may not only slow the progress of Alzheimer's, but may also reverse plaque-related brain injuries associated with AD. - November 27, 2007 - Samaritan Pharmaceuticals

Dr. Steve Bannister’s expertise requested for several speaking engagements over the next year - October 31, 2007 - Xcelience, LLC

In a comparison study between schizophrenia treatments INVEGA™ (paliperidone) Extended-Release Tablets and SEROQUEL® (quetiapine), Invega patients saw schizophrenia symptom improvements as early as five days into therapy and continued through the end of the two-week study period. Results were presented today at the 20th Annual U.S. Psychiatric and Mental Health Congress in Orlando, Florida. - October 13, 2007 - Johnson & Johnson

Samaritan announced today the appointment of James E.K. Hildreth, M.D., a world renowned physician and HIV researcher, to its Scientific Advisory Board. The work of Dr. Hildreth in HIV/AIDS dates back to 1986 and focuses on blocking HIV infection by learning how HIV gets into cells. He has published more than 80 scientific articles and holds six patents. - October 03, 2007 - Samaritan Pharmaceuticals

Samaritan announced that it has entered into an exclusive licensing agreement with Georgetown University for a patent covering the Peripheral Benzodiazepine Receptor (PBR) which has led to Cancer drug candidates with the ability to inhibit cancerous tumors; and an imaging technique that could possibly distinguish cancerous tumors for a more targeted and improved chemotherapy. - August 21, 2007 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals has exclusively licensed a patent application entitled "Structure Based Drug Design of Steroid Inhibitors" from Georgetown University. - August 16, 2007 - Samaritan Pharmaceuticals

The Tampa-based contract research organization acquires a brand new building. - July 23, 2007 - Xcelience, LLC

The Tampa-based Contract Research Organization signed a partnership that will form new opportunities in the pharmaceutical industry. - May 24, 2007 - Xcelience, LLC

Xcelience's implementation of the CFS1200 will allow its formulation scientists the opportunity to accelerate the drug development timeframe. - March 13, 2007 - Xcelience, LLC

Xcelience achives its third successful audit. - March 09, 2007 - Xcelience, LLC

XpertXchange will initiate dialogue between Xcelience scientists and drug development professionals. - March 02, 2007 - Xcelience, LLC

The launch of Xpert Consulting will provide supplemental services to assist clients. - January 17, 2007 - Xcelience, LLC

Pharmacists at Teregen Labs can prepare diluted insulin in response to the growing need not met through retail pharmacies. When a Diluted Insulin Injection is needed, often when a patient is on an insulin pump, things typically get worse for diabetes sufferers. Teregen Labs regularly dilutes Insulin for diabetes sufferers with a valid prescription from their physician faxed into their pharmacy for an affordable price. - January 16, 2007 - Teregen Labs

Hovione has increased its range of services and multi-scale facilities in cGMP Spray Drying, an advanced particle design technology. Building on its accumulated expertise in all major areas of API development and cGMP manufacture, a full range of cGMP Spray Drying facilities operating at lab, pilot and industrial scale have now been installed at Hovione's API manufacturing plant in Europe and are currently being installed at Hovione’s Technology Transfer Centre in New Jersey, USA. - August 26, 2005 - Hovione